CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

Rhea-AI Summary

CVRx (NASDAQ: CVRX) announced that Devoted Health has implemented a Medicare Advantage coverage policy for Barostim therapy, effective July 17, 2026. Devoted Health covers approximately 466,000 Medicare Advantage members across 29 states and is the eighth largest Medicare Advantage insurer in the U.S.

The policy covers Barostim for patients within its current FDA-approved indication and for patients enrolled in the BENEFIT-HF heart failure trial. Together with Humana’s existing Barostim coverage, these policies represent about 21% of Medicare Advantage enrollment. Additional 2026 milestones include the start of Category I CPT codes for the Barostim procedure and CMS Category B IDE coverage for BENEFIT-HF trial patients.

Positive

• Devoted Health Medicare Advantage coverage for Barostim effective July 17, 2026
• 466,000 Devoted Health Medicare Advantage members across 29 states potentially addressable
• Barostim coverage includes both FDA-indicated patients and BENEFIT-HF trial participants
• Devoted Health and Humana Barostim policies cover about 21% of Medicare Advantage enrollment
• Category I CPT codes for Barostim procedure effective January 2026
• CMS Category B IDE coverage granted for BENEFIT-HF trial patients

Negative

• None.

Market reaction after coverage policy update: CVRX +3.17%

+3.17% $2.93 25.9x vol

15m delay

+3.17% Vs previous close

$2.93 Last Price

$2.85 $3.02 Day Range

$78.06M Market Cap

25.9x Rel. Volume

Following this news, CVRX has gained 3.17%, reflecting a moderate positive market reaction. The stock is currently trading at $2.93. Trading volume is exceptionally heavy at 25.9x the average, suggesting very strong buying interest.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

COO Brent Binkowski’s 26,223-share purchase on Aug. 13 was recorded alongside 1,309 shares sold. Tha...

Analysis

COO Brent Binkowski’s 26,223-share purchase on Aug. 13 was recorded alongside 1,309 shares sold. That Net Buying record adds context to the coverage-policy announcement; the S-3 shelf’s effectiveness field was false.

Key Figures

Policy effective date: July 17, 2026 Medicare Advantage members: approximately 466,000 members States covered: 29 states +2 more

5 metrics

Policy effective date July 17, 2026 Devoted Health Medicare Advantage coverage policy

Medicare Advantage members approximately 466,000 members Devoted Health coverage across 29 states

States covered 29 states Devoted Health Medicare Advantage enrollment

Enrollment represented approximately 21% Devoted Health and Humana policies combined

Medicare Advantage enrollment rank eighth largest Devoted Health enrollment in the U.S.

Historical Context

5 past events · Latest: Aug 11 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 11	Sales leadership transition	Negative	+9.9%	Chief revenue officer departed; interim sales leader appointed during commercial outlook revision.
Aug 06	2Q26 earnings report	Negative	-59.8%	Revenue increased, but guidance and operational headwinds accompanied a substantial negative price reaction.
Jul 28	Conference presentation notice	Neutral	+1.4%	Management presentation announcement preceded a 1.43% positive price reaction.
Jul 23	Earnings date announcement	Neutral	-3.1%	Second-quarter reporting schedule preceded a 3.07% negative price reaction.
Jun 09	CFO transition	Negative	-3.7%	Chief financial officer transition and successor search preceded a 3.7% negative reaction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent reactions were mixed: the sales-leadership item rose 9.92%, while the earnings release fell 59.76%, with no consistent direction across news categories.

Key Terms

medicare advantage, category i cpt codes, fda-approved indication

3 terms

medicare advantage regulatory

"Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy"

Medicare Advantage is a type of health insurance plan offered by private companies that covers services traditionally provided by government-run Medicare. Think of it as a bundled package that combines hospital, doctor, and other medical care into one plan, often with added benefits. For investors, it matters because the popularity and profitability of these plans can influence healthcare companies and the broader health insurance industry.

category i cpt codes regulatory

"In January, Category I CPT codes went into effect for the Barostim procedure"

Category I CPT codes are standardized numeric labels used by doctors and hospitals to describe common medical procedures and services for billing and insurance purposes. Think of them like a universal price tag and barcode for a medical service: having a Category I code makes it easier for providers to bill insurers and for payers to decide coverage, which directly affects how reliably and quickly a procedure generates revenue and is adopted across the health system.

fda-approved indication regulatory

"patients meeting its current FDA-approved indication"

A FDA-approved indication is the specific disease, condition, patient population, or clinical use that the U.S. Food and Drug Administration has formally reviewed and authorized a drug, biologic, or medical device to treat, prevent, diagnose, or manage. It matters to investors because approval defines what the product can be marketed and reimbursed for and shapes its potential sales and competitive landscape—similar to a permit that legally limits where and how a product can be used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17, 2026. Devoted Health, a national health insurance company with the eighth largest Medicare Advantage enrollment in the U.S., provides coverage to approximately 466,000 Medicare Advantage members across 29 states.

The new policy covers Barostim for patients meeting its current FDA-approved indication as well as patients enrolled in the BENEFIT-HF trial, the landmark heart failure study evaluating Barostim in a significantly expanded patient population initiated earlier this year.

“We are pleased that Devoted Health, one of the fastest-growing Medicare Advantage plans in the U.S., has issued a policy covering Barostim,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “Together, the Devoted Health and Humana coverage policies represent approximately 21 percent of Medicare Advantage enrollment and mark continued progress toward broader, more consistent coverage for Barostim and greater access to the therapy for patients living with heart failure.”

The Devoted Health policy builds on several other positive reimbursement developments for Barostim in 2026. In January, Category I CPT codes went into effect for the Barostim procedure, and the Centers for Medicare & Medicaid Services (CMS) approved Category B IDE coverage for patients enrolled in the BENEFIT-HF trial. In May, Humana issued a Barostim therapy coverage policy for Medicare Advantage members and patients enrolled in the BENEFIT-HF trial.

About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

FAQ

What did CVRx (NASDAQ: CVRX) announce about Devoted Health Medicare Advantage coverage for Barostim on August 24, 2026?

CVRx announced that Devoted Health adopted a Medicare Advantage coverage policy for Barostim therapy effective July 17, 2026. According to CVRx, the policy applies to eligible heart failure patients within the FDA-approved indication and to participants in the BENEFIT-HF clinical trial.

How many Medicare Advantage members could be impacted by Devoted Health’s Barostim coverage for CVRX?

Devoted Health covers approximately 466,000 Medicare Advantage members across 29 states. According to CVRx, these members are now within a plan that has a formal coverage policy for Barostim therapy, subject to meeting the FDA-approved indication or BENEFIT-HF trial enrollment.

Does Devoted Health’s Medicare Advantage policy cover Barostim for BENEFIT-HF trial patients of CVRx?

Yes, Devoted Health’s Medicare Advantage policy covers Barostim for patients enrolled in the BENEFIT-HF trial. According to CVRx, the policy also includes patients who meet the current FDA-approved indication, broadening access for heart failure patients under this plan.

What percentage of Medicare Advantage enrollment do Devoted Health and Humana Barostim policies represent for CVRX?

According to CVRx, Devoted Health and Humana Barostim coverage policies together represent approximately 21% of total Medicare Advantage enrollment. This combined coverage marks progress toward broader and more consistent reimbursement for Barostim therapy among U.S. Medicare Advantage beneficiaries.

What reimbursement milestones did CVRx report for Barostim therapy in 2026?

In 2026, Category I CPT codes for the Barostim procedure took effect in January. According to CVRx, CMS also approved Category B IDE coverage for BENEFIT-HF trial patients, and Humana and Devoted Health each issued Medicare Advantage coverage policies for Barostim.

How does the new Devoted Health coverage policy support CVRx’s Barostim BENEFIT-HF heart failure trial?

The Devoted Health policy explicitly covers Barostim for patients enrolled in the BENEFIT-HF trial. According to CVRx, this coverage complements CMS Category B IDE approval, supporting patient access to the therapy while the landmark heart failure study evaluates an expanded patient population.